Pfizer Income from Continuous Operations 2012-2026 | PFE
Pfizer annual/quarterly income from continuous operations history and growth rate from 2012 to 2026. Income from continuous operations can be defined as a company's total income or loss before discontinued operations, extraordinary items, preferred stock dividends and accounting change
- Pfizer income from continuous operations for the quarter ending March 31, 2026 was $2.709B, a 8.88% decline year-over-year.
- Pfizer income from continuous operations for the twelve months ending March 31, 2026 was $7.522B, a 4.74% decline year-over-year.
- Pfizer annual income from continuous operations for 2025 was $7.787B, a 3.28% decline from 2024.
- Pfizer annual income from continuous operations for 2024 was $8.051B, a 270.67% increase from 2023.
- Pfizer annual income from continuous operations for 2023 was $2.172B, a 93.08% decline from 2022.
|
Pfizer Annual Income from Continuous Operations (Millions of US $) |
|
|---|---|
| 2025 | $7,787 |
| 2024 | $8,051 |
| 2023 | $2,172 |
| 2022 | $31,401 |
| 2021 | $22,459 |
| 2020 | $6,666 |
| 2019 | $10,738 |
| 2018 | $3,861 |
| 2017 | $21,353 |
| 2016 | $7,229 |
| 2015 | $6,975 |
| 2014 | $9,119 |
| 2013 | $11,410 |
| 2012 | $9,021 |
| 2011 | $7,860 |
|
Pfizer Quarterly Income from Continuous Operations (Millions of US $) |
|
|---|---|
| 2026-03-31 | $2,709 |
| 2025-12-31 | $-1,640 |
| 2025-09-30 | $3,550 |
| 2025-06-30 | $2,903 |
| 2025-03-31 | $2,973 |
| 2024-12-31 | $411 |
| 2024-09-30 | $4,481 |
| 2024-06-30 | $31 |
| 2024-03-31 | $3,128 |
| 2023-12-31 | $-3,335 |
| 2023-09-30 | $-2,388 |
| 2023-06-30 | $2,340 |
| 2023-03-31 | $5,555 |
| 2022-12-31 | $5,000 |
| 2022-09-30 | $8,645 |
| 2022-06-30 | $9,877 |
| 2022-03-31 | $7,879 |
| 2021-12-31 | $3,578 |
| 2021-09-30 | $8,171 |
| 2021-06-30 | $5,825 |
| 2021-03-31 | $4,885 |
| 2020-12-31 | $662 |
| 2020-09-30 | $917 |
| 2020-06-30 | $2,604 |
| 2020-03-31 | $2,483 |
| 2019-12-31 | $-5,887 |
| 2019-09-30 | $7,680 |
| 2019-06-30 | $5,056 |
| 2019-03-31 | $3,889 |
| 2018-12-31 | $-7,700 |
| 2018-09-30 | $4,111 |
| 2018-06-30 | $3,879 |
| 2018-03-31 | $3,571 |
| 2017-12-31 | $12,288 |
| 2017-09-30 | $2,858 |
| 2017-06-30 | $3,077 |
| 2017-03-31 | $3,130 |
| 2016-12-31 | $764 |
| 2016-09-30 | $1,355 |
| 2016-06-30 | $2,062 |
| 2016-03-31 | $3,048 |
| 2015-12-31 | $-166 |
| 2015-09-30 | $2,130 |
| 2015-06-30 | $2,635 |
| 2015-03-31 | $2,376 |
| 2014-12-31 | $1,257 |
| 2014-09-30 | $2,676 |
| 2014-06-30 | $2,921 |
| 2014-03-31 | $2,265 |
| 2013-12-31 | $2,631 |
| 2013-09-30 | $2,588 |
| 2013-06-30 | $3,575 |
| 2013-03-31 | $2,616 |
| 2012-12-31 | $1,308 |
| 2012-09-30 | $2,989 |
| 2012-06-30 | $3,000 |
| 2012-03-31 | $1,724 |
| 2011-12-31 | $790 |
| 2011-09-30 | $2,325 |
| 2011-06-30 | $2,521 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $153.074B | $62.579B |
| Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $887.629B | 38.81 |
| Johnson & Johnson (JNJ) | United States | $574.358B | 22.08 |
| AbbVie (ABBV) | United States | $367.673B | 20.79 |
| Roche Holding AG (RHHBY) | Switzerland | $318.782B | 0.00 |
| Merck (MRK) | United States | $299.893B | 13.54 |
| Novartis AG (NVS) | Switzerland | $293.951B | 17.16 |
| Novo Nordisk (NVO) | Denmark | $167.527B | 9.60 |
| Sanofi (SNY) | France | $114.048B | 10.56 |
| Bayer (BAYRY) | Germany | $46.178B | 8.70 |
| Innoviva (INVA) | United States | $1.760B | 5.88 |